RayKnowChina Research Map
Shortlist0

RecruitingOesophageal squamous cell carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Sun Yat-sen University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)First Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07863141, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Pathologically confirmed esophageal squamous cell carcinoma;

    Inclusion criterion 1

  3. Unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma that has not received prior systemic therapy, or recurrence more than 6 months after completion of (neo)adjuvant/radical therapy;

    Inclusion criterion 2

    Enrollment window: randomization must be performed within 42 days after completion of the last treatment (including local therapy);

    Inclusion criterion 4

  4. ECOG performance status score of 0-1;

    Inclusion criterion 7

  5. Immune-related deficiency: known history of immunodeficiency, including positive HIV test, or other acquired or congenital immunodeficiency diseases, or a history of solid organ transplantation;

    Exclusion criterion 16

  6. Female patients who are pregnant or breastfeeding;

    Exclusion criterion 17

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07863141, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Pathologically confirmed esophageal squamous cell carcinoma;
  • Unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma that has not received prior systemic therapy, or recurrence more than 6 months after completion of (neo)adjuvant/radical therapy;
  • Patients who have completed 4-6 cycles of PD-1 inhibitor combined with platinum-based doublet chemotherapy, who may receive local therapy if the investigator determines a benefit from local treatment, and who have not progressed after the above treatment;
  • Enrollment window: randomization must be performed within 42 days after completion of the last treatment (including local therapy);
  • Expected survival greater than 3 months;
  • Age 18-75 years;
  • ECOG performance status score of 0-1;
  • Laboratory tests within 7 days before the first dose must meet the following requirements: Hematology: neutrophils ≥1.5×10\^9/L, platelets ≥75.0×10\^9/L, hemoglobin ≥80 g/L; Liver function: total bilirubin ≤1.5 × ULN, ALT/AST ≤2.5 × ULN (≤5 × ULN if liver metastasis is present); Renal function: serum creatinine ≤1.5 × ULN or creatinine clearance >60 mL/min; Coagulation function: international normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN; no concomitant severe organic disease;
  • The patient understands the details of the trial and has signed the informed consent form.

Exclusion Criteria:

  • Known or suspected allergy to the study drug or to any drug administered in connection with this trial;
  • Patients who can be cured by surgery or radiotherapy;
  • Endoscopic or imaging findings indicating obvious deep ulceration of the esophageal lesion; or obvious invasion of adjacent vital organs (such as the aorta or trachea) by the tumor with a very high risk of bleeding or perforation; or formation of an esophageal-tracheal fistula/esophageal-mediastinal fistula;
  • Presence of complete esophageal obstruction requiring interventional treatment; prior esophageal or tracheal stent placement before enrollment; or presence of factors that significantly affect the absorption of oral drugs (anlotinib), such as inability to swallow tablets, chronic diarrhea, or intestinal obstruction;
  • Prior treatment with anlotinib; or treatment with other VEGF small-molecule tyrosine kinase inhibitors (TKIs) within 6 months before the first dose (Note: patients who received other VEGF TKIs during (neo)adjuvant/radical therapy and whose last dose was more than 6 months before this recurrence/progression may be enrolled);
  • Patients who experienced grade ≥3 immune-related adverse events (irAEs) during PD-1 inhibitor combined with chemotherapy, or for whom the investigator considers continued PD-1 inhibitor treatment inappropriate due to toxicities;
  • Presence of symptomatic brain metastases or meningeal metastases (Note: patients whose brain metastases have been locally treated and remained stable for at least 4 weeks before enrollment without the need for glucocorticoids to reduce intracranial pressure may be allowed to enroll);
  • Patients with a history of other malignancies besides esophageal cancer before enrollment, except for melanoma skin cancer, carcinoma in situ of the cervix, or cured early-stage prostate cancer;
  • Poor blood pressure control despite antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg); or patients using two or more antihypertensive drugs to control blood pressure; patients with a history of hypertensive crisis or hypertensive encephalopathy;
  • Severe cardiovascular disease: myocardial infarction, severe/unstable angina, NYHA class III-IV heart failure, left ventricular ejection fraction (LVEF) <50% on echocardiography, severe arrhythmia requiring pharmacological intervention, or prior coronary/peripheral artery bypass grafting within 6 months before enrollment;
  • Bleeding tendency: clinically significant active bleeding within 2 months before screening (such as gastrointestinal bleeding, hematemesis, melena, etc., with a daily blood loss ≥2.5 mL); or patients with abnormal coagulation function, a bleeding tendency, or currently receiving thrombolytic or anticoagulant therapy (except prophylactic use of low-dose aspirin or low-molecular-weight heparin);
  • History of thrombosis: arterial or venous thrombotic events within 6 months before enrollment, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, or pulmonary embolism;
  • High renal risk: patients with urine protein ≥++ on urinalysis and confirmed 24-hour urinary protein >1.5 g;
  • Surgery and trauma: major surgery (such as thoracotomy or laparotomy) within 4 weeks before the first dose, or presence of long-term non-healing wounds or fractures, or expected need for major surgery during the study period;
  • Active infection: presence of active infection requiring intravenous systemic anti-infective therapy, or known active tuberculosis;
  • Immune-related deficiency: known history of immunodeficiency, including positive HIV test, or other acquired or congenital immunodeficiency diseases, or a history of solid organ transplantation;
  • Female patients who are pregnant or breastfeeding;
  • Investigator's judgment: presence of severe concomitant diseases (such as uncontrolled diabetes, severe liver or kidney disease, etc.), psychiatric disorders, or psychological, family, social, or other factors that the investigator considers may jeopardize patient safety and compliance.

Quoted from ClinicalTrials.gov, NCT07863141, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07863141, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07863141